drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00661 | DB12001 | 122 | 564 | [
"DDInter1928",
"DDInter7"
] | Verapamil | Abemaciclib | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes ... | Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the trea... | Moderate | 1 | [
[
[
122,
24,
564
]
],
[
[
122,
23,
868
],
[
868,
24,
564
]
],
[
[
122,
24,
392
],
[
392,
24,
564
]
],
[
[
122,
63,
600
],
[
600,
24,... | [
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
],
[
[
"Verapamil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vemurafenib"
],
[
... | Verapamil may cause a minor interaction that can limit clinical effects when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatini... |
DB14444 | DB14762 | 151 | 994 | [
"DDInter924",
"DDInter1602"
] | Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) | Risankizumab | A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immuno... | Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23). It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease... | Moderate | 1 | [
[
[
151,
24,
994
]
],
[
[
151,
63,
4
],
[
4,
24,
994
]
],
[
[
151,
24,
676
],
[
676,
64,
994
]
],
[
[
151,
63,
1510
],
[
1510,
25,
... | [
[
[
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risankizumab"
]
],
[
[
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiola... | Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Risankizumab
Influ... |
DB00771 | DB09272 | 262 | 412 | [
"DDInter397",
"DDInter632"
] | Clidinium | Eluxadoline | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the tr... | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system ... | Moderate | 1 | [
[
[
262,
24,
412
]
],
[
[
262,
63,
1594
],
[
1594,
24,
412
]
],
[
[
262,
24,
543
],
[
543,
24,
412
]
],
[
[
262,
40,
1413
],
[
1413,
... | [
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
... | Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperam... |
DB06403 | DB08875 | 1,204 | 1,618 | [
"DDInter62",
"DDInter262"
] | Ambrisentan | Cabozantinib | Ambrisentan is an orally active selective type A endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension. It is approved in Europe, Canada and the United States for use as a single agent to improve exercise ability and delay clinical worsening. In addition, it is approved in the Un... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Moderate | 1 | [
[
[
1204,
24,
1618
]
],
[
[
1204,
24,
384
],
[
384,
63,
1618
]
],
[
[
1204,
24,
850
],
[
850,
24,
1618
]
],
[
[
1204,
62,
86
],
[
86,
... | [
[
[
"Ambrisentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Ambrisentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
... | Ambrisentan may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Ambrisentan may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedot... |
DB09034 | DB12130 | 1,313 | 1,017 | [
"DDInter1733",
"DDInter1094"
] | Suvorexant | Lorlatinib | Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia. | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
1313,
24,
1017
]
],
[
[
1313,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
1313,
24,
1421
],
[
1421,
63,
1017
]
],
[
[
1313,
63,
1491
],
[
14... | [
[
[
"Suvorexant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Suvorexant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Suvorexant may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Suvorexant may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban and Betrixab... |
DB01155 | DB09104 | 872 | 286 | [
"DDInter813",
"DDInter1118"
] | Gemifloxacin | Magnesium hydroxide | Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase... | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
872,
24,
286
]
],
[
[
872,
24,
820
],
[
820,
23,
286
]
],
[
[
872,
63,
401
],
[
401,
23,
286
]
],
[
[
872,
62,
752
],
[
752,
23,... | [
[
[
"Gemifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Gemifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
... | Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Prometha... |
DB00026 | DB06168 | 1,184 | 1,531 | [
"DDInter94",
"DDInter281"
] | Anakinra | Canakinumab | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Moderate | 1 | [
[
[
1184,
24,
1531
]
],
[
[
1184,
23,
1193
],
[
1193,
62,
1531
]
],
[
[
1184,
23,
1461
],
[
1461,
23,
1531
]
],
[
[
1184,
24,
523
],
[
523... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Anakinra",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
... | Anakinra may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Canakinumab
Anakinra may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin ... |
DB00193 | DB01259 | 534 | 392 | [
"DDInter1841",
"DDInter1024"
] | Tramadol | Lapatinib | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatmen... | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
534,
24,
392
]
],
[
[
534,
6,
8374
],
[
8374,
45,
392
]
],
[
[
534,
18,
20113
],
[
20113,
57,
392
]
],
[
[
534,
21,
29429
],
[
29429,
... | [
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Tramadol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Tramadol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lapatinib (Compound)
Tramadol (Compound) downregulates IER3 (Gene) and IER3 (Gene) is downregulated by Lapatinib (Compound)
Tramadol (Compound) causes Infestation NOS (Side Effect) and Infestation NOS (Side Effect) is caused by Lapatinib (Compound)
T... |
DB01377 | DB14491 | 1,283 | 428 | [
"DDInter1119",
"DDInter725"
] | Magnesium oxide | Ferrous fumarate | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Used in treatment of iron deficiency anemia. | Moderate | 1 | [
[
[
1283,
24,
428
]
],
[
[
1283,
63,
1096
],
[
1096,
23,
428
]
],
[
[
1283,
62,
752
],
[
752,
23,
428
]
],
[
[
1283,
63,
1008
],
[
1008,
... | [
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
]
],
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenoli... | Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate
Magnesium oxide may cause a minor interaction that can limit clinical effects when taken ... |
DB01150 | DB01172 | 315 | 416 | [
"DDInter327",
"DDInter1004"
] | Cefprozil | Kanamycin | Cefprozil is a cephalosporin antibiotic that is commonly employed to treat a variety of bacterial infections, including those of the ear and skin, bronchitis, and others. | Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate. | Moderate | 1 | [
[
[
315,
24,
416
]
],
[
[
315,
21,
28680
],
[
28680,
60,
416
]
],
[
[
315,
1,
164
],
[
164,
24,
416
]
],
[
[
315,
1,
1024
],
[
1024,
... | [
[
[
"Cefprozil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
]
],
[
[
"Cefprozil",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v} (Co... | Cefprozil (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Kanamycin (Compound)
Cefprozil (Compound) resembles Cefalotin (Compound) and Cefalotin may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin
Cefprozil (Compound) resembles Cefpodoxime (Compound) and Ce... |
DB09291 | DB11853 | 741 | 230 | [
"DDInter1615",
"DDInter1577"
] | Rolapitant | Relugolix | Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its l... | Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under th... | Major | 2 | [
[
[
741,
25,
230
]
],
[
[
741,
64,
129
],
[
129,
23,
230
]
],
[
[
741,
63,
1094
],
[
1094,
23,
230
]
],
[
[
741,
25,
1456
],
[
1456,
... | [
[
[
"Rolapitant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Relugolix"
]
],
[
[
"Rolapitant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u... | Rolapitant may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Relugolix
Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin and Metreleptin may cau... |
DB06206 | DB06713 | 1,268 | 615 | [
"DDInter1719",
"DDInter1310"
] | Sugammadex | Norelgestromin | Sugammadex is a selective relaxant binding agent indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery. Rocuronium bromide and vecuronium bromide are neuromuscular blocking medications that cause temporary paralysis and are especially useful for general ane... | Norelgestromin is a drug used in contraception. Norelgestromin is the active progestin responsible for the progestational activity that occurs in women after application of ORTHO EVRA patch. | Major | 2 | [
[
[
1268,
25,
615
]
],
[
[
1268,
64,
566
],
[
566,
1,
615
]
],
[
[
1268,
64,
1336
],
[
1336,
40,
615
]
],
[
[
1268,
64,
566
],
[
566,
... | [
[
[
"Sugammadex",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Norelgestromin"
]
],
[
[
"Sugammadex",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levonorgestrel"
],
[
"Levonorgestrel",
... | Sugammadex may lead to a major life threatening interaction when taken with Levonorgestrel and Levonorgestrel (Compound) resembles Norelgestromin (Compound)
Sugammadex may lead to a major life threatening interaction when taken with Etonogestrel and Etonogestrel (Compound) resembles Norelgestromin (Compound)
Sugammadex... |
DB00867 | DB09330 | 1,052 | 985 | [
"DDInter1606",
"DDInter1352"
] | Ritodrine | Osimertinib | Adrenergic beta-agonist used to control premature labor. | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Major | 2 | [
[
[
1052,
25,
985
]
],
[
[
1052,
35,
480
],
[
480,
24,
985
]
],
[
[
1052,
24,
1559
],
[
1559,
24,
985
]
],
[
[
1052,
23,
1220
],
[
1220,
... | [
[
[
"Ritodrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Ritodrine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Ritodrine (Compound) resembles Formoterol (Compound) and Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Ritodrine may cause a moderate interaction that could e... |
DB00910 | DB01070 | 1,041 | 1,098 | [
"DDInter1394",
"DDInter558"
] | Paricalcitol | Dihydrotachysterol | Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure. | A vitamin D that can be regarded as a reduction product of vitamin D2. | Major | 2 | [
[
[
1041,
25,
1098
]
],
[
[
1041,
40,
1113
],
[
1113,
1,
1098
]
],
[
[
1041,
1,
11418
],
[
11418,
40,
1098
]
],
[
[
1041,
64,
386
],
[
386... | [
[
[
"Paricalcitol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dihydrotachysterol"
]
],
[
[
"Paricalcitol",
"{u} (Compound) resembles {v} (Compound)",
"Calcitriol"
],
[
"Calcitriol",
"{u} (Compound) resembles {... | Paricalcitol (Compound) resembles Calcitriol (Compound) and Calcitriol (Compound) resembles Dihydrotachysterol (Compound)
Paricalcitol (Compound) resembles Alfacalcidol (Compound) and Alfacalcidol (Compound) resembles Dihydrotachysterol (Compound)
Paricalcitol may lead to a major life threatening interaction when taken... |
DB01142 | DB01148 | 1,264 | 1,128 | [
"DDInter593",
"DDInter738"
] | Doxepin | Flavoxate | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist. [PubChem] | Moderate | 1 | [
[
[
1264,
24,
1128
]
],
[
[
1264,
6,
7992
],
[
7992,
45,
1128
]
],
[
[
1264,
21,
29817
],
[
29817,
60,
1128
]
],
[
[
1264,
24,
537
],
[
53... | [
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flavoxate"
]
],
[
[
"Doxepin",
"{u} (Compound) binds {v} (Gene)",
"CHRM1"
],
[
"CHRM1",
"{u} (Gene) is bound by {v} (Compound)",
"F... | Doxepin (Compound) binds CHRM1 (Gene) and CHRM1 (Gene) is bound by Flavoxate (Compound)
Doxepin (Compound) causes Hyperpyrexia (Side Effect) and Hyperpyrexia (Side Effect) is caused by Flavoxate (Compound)
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine ma... |
DB01238 | DB08912 | 673 | 1,040 | [
"DDInter118",
"DDInter462"
] | Aripiprazole | Dabrafenib | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects thr... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
673,
24,
1040
]
],
[
[
673,
6,
4973
],
[
4973,
45,
1040
]
],
[
[
673,
7,
8733
],
[
8733,
46,
1040
]
],
[
[
673,
18,
2183
],
[
2183,
... | [
[
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Aripiprazole",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)... | Aripiprazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dabrafenib (Compound)
Aripiprazole (Compound) upregulates PHGDH (Gene) and PHGDH (Gene) is upregulated by Dabrafenib (Compound)
Aripiprazole (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Dabrafenib (Compound)
Aripiprazo... |
DB00104 | DB13985 | 966 | 546 | [
"DDInter1323",
"DDInter1108"
] | Octreotide | Lutetium Lu 177 dotatate | Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may... | A 177Lu-labeled somatostatin analog peptide, Lutetium Lu 177 dotatate belongs to an emerging form of treatments called Peptide Receptor Radionuclide Therapy (PRRT), which involves targeting tumours with molecules carrying radioactive particles that bind to specific receptors expressed by the tumour. Lutetium Lu 177 dot... | Moderate | 1 | [
[
[
966,
24,
546
]
],
[
[
966,
24,
123
],
[
123,
24,
546
]
],
[
[
966,
40,
1154
],
[
1154,
24,
546
]
],
[
[
966,
24,
676
],
[
676,
6... | [
[
[
"Octreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lutetium Lu 177 dotatate"
]
],
[
[
"Octreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
... | Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Lutetium Lu 177 dotatate
Octreotide (Compound) resembles Pasireotide (Compound) and Pasireotide may cause a moderate interact... |
DB00388 | DB01088 | 1,636 | 714 | [
"DDInter1453",
"DDInter908"
] | Phenylephrine | Iloprost | Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939. | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Moderate | 1 | [
[
[
1636,
24,
714
]
],
[
[
1636,
24,
1121
],
[
1121,
24,
714
]
],
[
[
1636,
24,
1592
],
[
1592,
63,
714
]
],
[
[
1636,
1,
874
],
[
874,
... | [
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
]
],
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisoprolol"
],
... | Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Bisoprolol and Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Iloprost
Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Nebivolol and Neb... |
DB09048 | DB11718 | 555 | 927 | [
"DDInter1284",
"DDInter640"
] | Netupitant | Encorafenib | Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy. Netupitant is a neurokinin 1 receptor antagonist. The combination drug i... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Major | 2 | [
[
[
555,
25,
927
]
],
[
[
555,
63,
1324
],
[
1324,
24,
927
]
],
[
[
555,
25,
484
],
[
484,
63,
927
]
],
[
[
555,
62,
1101
],
[
1101,
... | [
[
[
"Netupitant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Netupitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglit... | Netupitant may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Netupitant may lead to a major life threatening interaction when taken with Entrectinib and Entrectinib may... |
DB00420 | DB00694 | 508 | 51 | [
"DDInter1532",
"DDInter485"
] | Promazine | Daunorubicin | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Moderate | 1 | [
[
[
508,
24,
51
]
],
[
[
508,
6,
7950
],
[
7950,
45,
51
]
],
[
[
508,
7,
8606
],
[
8606,
46,
51
]
],
[
[
508,
18,
1918
],
[
1918,
57... | [
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
]
],
[
[
"Promazine",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",... | Promazine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Daunorubicin (Compound)
Promazine (Compound) upregulates ALDOC (Gene) and ALDOC (Gene) is upregulated by Daunorubicin (Compound)
Promazine (Compound) downregulates PCNA (Gene) and PCNA (Gene) is downregulated by Daunorubicin (Compound)
Promazine (Co... |
DB00397 | DB01105 | 1,466 | 222 | [
"DDInter1458",
"DDInter1665"
] | Phenylpropanolamine | Sibutramine | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Major | 2 | [
[
[
1466,
25,
222
]
],
[
[
1466,
5,
11585
],
[
11585,
44,
222
]
],
[
[
1466,
6,
7390
],
[
7390,
45,
222
]
],
[
[
1466,
21,
28698
],
[
2869... | [
[
[
"Phenylpropanolamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
]
],
[
[
"Phenylpropanolamine",
"{u} (Compound) treats {v} (Disease)",
"obesity"
],
[
"obesity",
"{u} (Disease) is treated by {... | Phenylpropanolamine (Compound) treats obesity (Disease) and obesity (Disease) is treated by Sibutramine (Compound)
Phenylpropanolamine (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Sibutramine (Compound)
Phenylpropanolamine (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by ... |
DB00348 | DB00673 | 254 | 723 | [
"DDInter1300",
"DDInter112"
] | Nitisinone | Aprepitant | Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1. It is sold under the brand name Orfadin. | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Moderate | 1 | [
[
[
254,
24,
723
]
],
[
[
254,
24,
875
],
[
875,
40,
723
]
],
[
[
254,
21,
28847
],
[
28847,
60,
723
]
],
[
[
254,
23,
307
],
[
307,
... | [
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
]
],
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
],
[... | Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant and Fosaprepitant (Compound) resembles Aprepitant (Compound)
Nitisinone (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Aprepitant (Compound)
Nitisinone may cause a minor int... |
DB00031 | DB05578 | 20 | 330 | [
"DDInter1764",
"DDInter1566"
] | Tenecteplase | Ramucirumab | Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at ... | Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stim... | Major | 2 | [
[
[
20,
25,
330
]
],
[
[
20,
24,
41
],
[
41,
63,
330
]
],
[
[
20,
24,
901
],
[
901,
24,
330
]
],
[
[
20,
24,
1317
],
[
1317,
25,
... | [
[
[
"Tenecteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ramucirumab"
]
],
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
],
[
"... | Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Ramucirumab
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Milnac... |
DB00731 | DB01324 | 1,144 | 178 | [
"DDInter1269",
"DDInter1490"
] | Nateglinide | Polythiazide | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826) | Moderate | 1 | [
[
[
1144,
24,
178
]
],
[
[
1144,
24,
674
],
[
674,
40,
178
]
],
[
[
1144,
63,
1014
],
[
1014,
40,
178
]
],
[
[
1144,
21,
28714
],
[
28714,... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polythiazide"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trichlormethiazide"
... | Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide and Trichlormethiazide (Compound) resembles Polythiazide (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Benzthiazide and Benzthiazide (Compound) resemble... |
DB00619 | DB01132 | 1,419 | 1,130 | [
"DDInter909",
"DDInter1472"
] | Imatinib | Pioglitazone | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Moderate | 1 | [
[
[
1419,
24,
1130
]
],
[
[
1419,
6,
12523
],
[
12523,
45,
1130
]
],
[
[
1419,
21,
28661
],
[
28661,
60,
1130
]
],
[
[
1419,
63,
303
],
[
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
]
],
[
[
"Imatinib",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
... | Imatinib (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Pioglitazone (Compound)
Imatinib (Compound) causes Acute coronary syndrome (Side Effect) and Acute coronary syndrome (Side Effect) is caused by Pioglitazone (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when take... |
DB05679 | DB10276 | 1,683 | 1,624 | [
"DDInter1907",
"DDInter1623"
] | Ustekinumab | Rotavirus vaccine | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Rotavirus commonly infects children and infants causing severe diarrhea and vomiting leading to potentially fatal dehydration. Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq and Rotarix. Rotateq is a live vaccine consisting of 5 reassorted human-bovine viral strains. Rotar... | Major | 2 | [
[
[
1683,
25,
1624
]
],
[
[
1683,
63,
617
],
[
617,
24,
1624
]
],
[
[
1683,
63,
552
],
[
552,
25,
1624
]
],
[
[
1683,
25,
1583
],
[
1583,
... | [
[
[
"Ustekinumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
],
[
"B... | Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Rotavirus vaccine
Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Carmustine a... |
DB00477 | DB00836 | 216 | 543 | [
"DDInter363",
"DDInter1088"
] | Chlorpromazine | Loperamide | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Moderate | 1 | [
[
[
216,
24,
543
]
],
[
[
216,
24,
649
],
[
649,
1,
543
]
],
[
[
216,
24,
262
],
[
262,
24,
543
]
],
[
[
216,
63,
1242
],
[
1242,
24... | [
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
... | Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol (Compound) resembles Loperamide (Compound)
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Clidinium and Clidinium may cause a moderate interaction that... |
DB00736 | DB11613 | 660 | 1,519 | [
"DDInter676",
"DDInter1924"
] | Esomeprazole | Velpatasvir | Esomeprazole, sold under the brand name Nexium, is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory... | Velpatasvir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Major | 2 | [
[
[
660,
25,
1519
]
],
[
[
660,
24,
594
],
[
594,
24,
1519
]
],
[
[
660,
63,
467
],
[
467,
24,
1519
]
],
[
[
660,
1,
379
],
[
379,
2... | [
[
[
"Esomeprazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Velpatasvir"
]
],
[
[
"Esomeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
],
[
"Bosuti... | Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Velpatasvir
Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Si... |
DB00787 | DB01024 | 387 | 1,096 | [
"DDInter25",
"DDInter1252"
] | Acyclovir | Mycophenolic acid | Acyclovir is a nucleotide analog antiviral used to treat herpes simplex, _Varicella zoster_, herpes zoster, herpes labialis, and acute herpetic keratitis[L7303,L7315,L7318,L7321,L7324,L7327]. Acyclovir is generally used first line in the treatment of these viruses and some products are indicated for patients as young a... | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a c... | Minor | 0 | [
[
[
387,
23,
1096
]
],
[
[
387,
62,
955
],
[
955,
1,
1096
]
],
[
[
387,
18,
8814
],
[
8814,
46,
1096
]
],
[
[
387,
7,
5144
],
[
5144,
... | [
[
[
"Acyclovir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Acyclovir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mycophenolate mofetil"
... | Acyclovir may cause a minor interaction that can limit clinical effects when taken with Mycophenolate mofetil and Mycophenolate mofetil (Compound) resembles Mycophenolic acid (Compound)
Acyclovir (Compound) downregulates GAA (Gene) and GAA (Gene) is upregulated by Mycophenolic acid (Compound)
Acyclovir (Compound) upreg... |
DB00286 | DB00491 | 380 | 127 | [
"DDInter439",
"DDInter1217"
] | Conjugated estrogens | Miglitol | The conjugated estrogens are noncrystalline mixtures of purified female sex hormones obtained either by its isolation from the urine of pregnant mares or by synthetic generation from vegetal material. Both of these products are later conjugated to natrium sulfate by ester bonds in order to make them more water soluble.... | Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the bod... | Moderate | 1 | [
[
[
380,
24,
127
]
],
[
[
380,
21,
29180
],
[
29180,
60,
127
]
],
[
[
380,
24,
1486
],
[
1486,
63,
127
]
],
[
[
380,
63,
245
],
[
245,
... | [
[
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miglitol"
]
],
[
[
"Conjugated estrogens",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal distension"
],
[
"Abdominal diste... | Conjugated estrogens (Compound) causes Abdominal distension (Side Effect) and Abdominal distension (Side Effect) is caused by Miglitol (Compound)
Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interactio... |
DB00176 | DB06595 | 529 | 1,491 | [
"DDInter770",
"DDInter1214"
] | Fluvoxamine | Midostaurin | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
529,
24,
1491
]
],
[
[
529,
23,
1135
],
[
1135,
62,
1491
]
],
[
[
529,
24,
761
],
[
761,
24,
1491
]
],
[
[
529,
24,
1017
],
[
1017,
... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Fluvoxamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Fluvoxamine may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxaglip... |
DB08903 | DB09570 | 996 | 1,480 | [
"DDInter170",
"DDInter1002"
] | Bedaquiline | Ixazomib | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affe... | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortez... | Moderate | 1 | [
[
[
996,
24,
1480
]
],
[
[
996,
63,
268
],
[
268,
24,
1480
]
],
[
[
996,
24,
98
],
[
98,
24,
1480
]
],
[
[
996,
25,
1017
],
[
1017,
... | [
[
[
"Bedaquiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Bedaquiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2b"
... | Bedaquiline may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Bedaquiline may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00305 | DB01041 | 377 | 770 | [
"DDInter1232",
"DDInter1789"
] | Mitomycin | Thalidomide | Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of th... | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Major | 2 | [
[
[
377,
25,
770
]
],
[
[
377,
7,
7720
],
[
7720,
45,
770
]
],
[
[
377,
18,
4830
],
[
4830,
46,
770
]
],
[
[
377,
7,
3163
],
[
3163,
... | [
[
[
"Mitomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
]
],
[
[
"Mitomycin",
"{u} (Compound) upregulates {v} (Gene)",
"PTGS2"
],
[
"PTGS2",
"{u} (Gene) is bound by {v} (Compound)",
"Thal... | Mitomycin (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Thalidomide (Compound)
Mitomycin (Compound) downregulates TGFBR2 (Gene) and TGFBR2 (Gene) is upregulated by Thalidomide (Compound)
Mitomycin (Compound) upregulates TSC22D3 (Gene) and TSC22D3 (Gene) is upregulated by Thalidomide (Compound)
Mitomy... |
DB00195 | DB00388 | 726 | 1,636 | [
"DDInter198",
"DDInter1453"
] | Betaxolol (ophthalmic) | Phenylephrine | Betaxolol is a propanolamine that is 3-aminopropane-1,2-diol in which the hydrogen of the primary hydoxy is substituted by a 4-[2-(cyclopropylmethoxy)ethyl]phenyl group and one of the hydrogens attached to the amino group is substituted by isopropyl. It is a selective beta1-receptor blocker and is used in the treatment... | Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939. | Moderate | 1 | [
[
[
726,
24,
1636
]
],
[
[
726,
24,
1148
],
[
1148,
63,
1636
]
],
[
[
726,
6,
7950
],
[
7950,
45,
1636
]
],
[
[
726,
21,
28711
],
[
28711,... | [
[
[
"Betaxolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylephrine"
]
],
[
[
"Betaxolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[... | Betaxolol may cause a moderate interaction that could exacerbate diseases when taken with Phenylephrine
Betaxolol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Phenylephrine
Be... |
DB00569 | DB05773 | 553 | 1,047 | [
"DDInter775",
"DDInter1848"
] | Fondaparinux | Trastuzumab emtansine | Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in he... | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Major | 2 | [
[
[
553,
25,
1047
]
],
[
[
553,
25,
848
],
[
848,
24,
1047
]
],
[
[
553,
64,
886
],
[
886,
24,
1047
]
],
[
[
553,
24,
643
],
[
643,
... | [
[
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",... | Fondaparinux may lead to a major life threatening interaction when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Fondaparinux may lead to a major life threatening interaction when taken with Ketorolac and Ketorolac may cause a mo... |
DB00016 | DB00790 | 787 | 664 | [
"DDInter671",
"DDInter1431"
] | Erythropoietin | Perindopril | Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells. It works by promoting the division and differentiation of committed erythroid progenitors in the bone marrow [FDA Label]. Epoetin alfa (Epoge) was developed by Amgen Inc. in 1983 as the first rhEPO commerc... | Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible fo... | Minor | 0 | [
[
[
787,
23,
664
]
],
[
[
787,
23,
1638
],
[
1638,
1,
664
]
],
[
[
787,
23,
954
],
[
954,
40,
664
]
],
[
[
787,
23,
1638
],
[
1638,
... | [
[
[
"Erythropoietin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Perindopril"
]
],
[
[
"Erythropoietin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Trandolapril"
],
... | Erythropoietin may cause a minor interaction that can limit clinical effects when taken with Trandolapril and Trandolapril (Compound) resembles Perindopril (Compound)
Erythropoietin may cause a minor interaction that can limit clinical effects when taken with Quinapril and Quinapril (Compound) resembles Perindopril (Co... |
DB00394 | DB00983 | 218 | 480 | [
"DDInter168",
"DDInter776"
] | Beclomethasone dipropionate | Formoterol | Beclomethasone dipropionate is a second-generation synthetic corticosteroid and diester of beclomethasone, which is structurally similar to [dexamethasone]. It is a prodrug of an active metabolite beclomethasone 17-monopropionate (17-BMP) which acts on the glucocorticoid receptor to mediates its therapeutic action. Bec... | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Minor | 0 | [
[
[
218,
23,
480
]
],
[
[
218,
23,
1148
],
[
1148,
63,
480
]
],
[
[
218,
5,
11649
],
[
11649,
44,
480
]
],
[
[
218,
21,
28719
],
[
28719,
... | [
[
[
"Beclomethasone dipropionate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Formoterol"
]
],
[
[
"Beclomethasone dipropionate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
... | Beclomethasone dipropionate may cause a minor interaction that can limit clinical effects when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Beclomethasone dipropionate (Compound) treats asthma (Disease) and asthma (Disease) is treate... |
DB08816 | DB11732 | 578 | 1,097 | [
"DDInter1802",
"DDInter1027"
] | Ticagrelor | Lasmiditan | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019.[L9338,L9356] It was also approved by the European Commission on August 17, 2022. Traditionally, the triptan class of anti-migraine medications (e.g. [sumatriptan]) have se... | Moderate | 1 | [
[
[
578,
24,
1097
]
],
[
[
578,
63,
1181
],
[
1181,
24,
1097
]
],
[
[
578,
24,
971
],
[
971,
63,
1097
]
],
[
[
578,
25,
384
],
[
384,
... | [
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
]
],
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terfenadine"
],
[
... | Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gi... |
DB00039 | DB00056 | 1,253 | 816 | [
"DDInter1380",
"DDInter814"
] | Palifermin | Gemtuzumab ozogamicin | Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004. | Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheami... | Moderate | 1 | [
[
[
1253,
24,
816
]
],
[
[
1253,
24,
869
],
[
869,
63,
816
]
],
[
[
1253,
24,
1064
],
[
1064,
64,
816
]
],
[
[
1253,
24,
869
],
[
869,
... | [
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gemtuzumab ozogamicin"
]
],
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]... | Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Gemtuzumab ozogamicin
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Cladribine a... |
DB08908 | DB14444 | 713 | 151 | [
"DDInter564",
"DDInter924"
] | Dimethyl fumarate | Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) | Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis.[A253942,L43752] The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MM... | A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immuno... | Moderate | 1 | [
[
[
713,
24,
151
]
],
[
[
713,
63,
66
],
[
66,
24,
151
]
],
[
[
713,
24,
1619
],
[
1619,
24,
151
]
],
[
[
713,
64,
375
],
[
375,
24,... | [
[
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Dimethyl fumarate",
"{u} may cause a moderate interactio... | Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Dimethyl fumarate may cause a ... |
DB01138 | DB08865 | 804 | 1,593 | [
"DDInter1726",
"DDInter448"
] | Sulfinpyrazone | Crizotinib | A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Moderate | 1 | [
[
[
804,
24,
1593
]
],
[
[
804,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
804,
7,
9242
],
[
9242,
46,
1593
]
],
[
[
804,
18,
4930
],
[
4930,
... | [
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Sulfinpyrazone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Com... | Sulfinpyrazone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Sulfinpyrazone (Compound) upregulates WDR7 (Gene) and WDR7 (Gene) is upregulated by Crizotinib (Compound)
Sulfinpyrazone (Compound) downregulates DLD (Gene) and DLD (Gene) is downregulated by Crizotinib (Compound)
Sulfinpy... |
DB00708 | DB01168 | 1,454 | 1,053 | [
"DDInter1718",
"DDInter1526"
] | Sufentanil | Procarbazine | Sufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. It is administered by the intravenous, epidural and sublingual routes. Also known as _Dsuvia_, the sublingual form is used for the management of acute pain in adults that is severe to w... | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Major | 2 | [
[
[
1454,
25,
1053
]
],
[
[
1454,
21,
28762
],
[
28762,
60,
1053
]
],
[
[
1454,
24,
100
],
[
100,
24,
1053
]
],
[
[
1454,
24,
830
],
[
830... | [
[
[
"Sufentanil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
]
],
[
[
"Sufentanil",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Comp... | Sufentanil (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Procarbazine (Compound)
Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB06699 | DB09078 | 774 | 1,228 | [
"DDInter493",
"DDInter1036"
] | Degarelix | Lenvatinib | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH... | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Moderate | 1 | [
[
[
774,
24,
1228
]
],
[
[
774,
62,
112
],
[
112,
23,
1228
]
],
[
[
774,
63,
1100
],
[
1100,
24,
1228
]
],
[
[
774,
24,
938
],
[
938,
... | [
[
[
"Degarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Degarelix",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Degarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Degarelix may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venla... |
DB00215 | DB06704 | 1,230 | 247 | [
"DDInter388",
"DDInter951"
] | Citalopram | Iobenguane (I-123) | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] C... | 2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound. | Moderate | 1 | [
[
[
1230,
24,
247
]
],
[
[
1230,
6,
7390
],
[
7390,
45,
247
]
],
[
[
1230,
21,
28787
],
[
28787,
60,
247
]
],
[
[
1230,
25,
820
],
[
820,
... | [
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iobenguane"
]
],
[
[
"Citalopram",
"{u} (Compound) binds {v} (Gene)",
"SLC6A2"
],
[
"SLC6A2",
"{u} (Gene) is bound by {v} (Compound)",... | Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane
Citalopram (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Iobenguane (Compound)
Citalopram (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Iobenguane (Compound)
Citalo... |
DB00794 | DB01041 | 759 | 770 | [
"DDInter1521",
"DDInter1789"
] | Primidone | Thalidomide | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
759,
24,
770
]
],
[
[
759,
6,
10215
],
[
10215,
45,
770
]
],
[
[
759,
21,
28714
],
[
28714,
60,
770
]
],
[
[
759,
24,
849
],
[
849,
... | [
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Primidone",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)"... | Primidone (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Thalidomide (Compound)
Primidone (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Thalidomide (Compound)
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyr... |
DB01095 | DB12332 | 671 | 1,619 | [
"DDInter769",
"DDInter1626"
] | Fluvastatin | Rucaparib | Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin belongs to a class of medications called statins and is used to r... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
671,
24,
1619
]
],
[
[
671,
63,
112
],
[
112,
23,
1619
]
],
[
[
671,
24,
309
],
[
309,
24,
1619
]
],
[
[
671,
63,
1419
],
[
1419,
... | [
[
[
"Fluvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Fluvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and ... |
DB00316 | DB00907 | 474 | 290 | [
"DDInter14",
"DDInter427"
] | Acetaminophen | Cocaine (topical) | Acetaminophen (paracetamol), also commonly known as _Tylenol_, is the most commonly taken analgesic worldwide and is recommended as first-line therapy in pain conditions by the World Health Organization (WHO). It is also used for its antipyretic effects, helping to reduce fever. This drug was initially approved by the ... | Cocaine can cause developmental toxicity and female reproductive toxicity according to an independent committee of scientific and health experts. | Moderate | 1 | [
[
[
474,
24,
290
]
],
[
[
474,
23,
85
],
[
85,
1,
290
]
],
[
[
474,
6,
12523
],
[
12523,
45,
290
]
],
[
[
474,
21,
28741
],
[
28741,
... | [
[
[
"Acetaminophen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cocaine"
]
],
[
[
"Acetaminophen",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Atropine"
],
[
... | Acetaminophen may cause a moderate interaction that could exacerbate diseases when taken with Cocaine
Acetaminophen may cause a minor interaction that can limit clinical effects when taken with Atropine and Atropine (Compound) resembles Cocaine (Compound)
Acetaminophen (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) i... |
DB00261 | DB01218 | 702 | 1,493 | [
"DDInter93",
"DDInter852"
] | Anagrelide | Halofantrine | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Major | 2 | [
[
[
702,
25,
1493
]
],
[
[
702,
18,
2183
],
[
2183,
57,
1493
]
],
[
[
702,
21,
28810
],
[
28810,
60,
1493
]
],
[
[
702,
24,
479
],
[
479,
... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
]
],
[
[
"Anagrelide",
"{u} (Compound) downregulates {v} (Gene)",
"CDC20"
],
[
"CDC20",
"{u} (Gene) is downregulated by {v} (Compound)"... | Anagrelide (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Halofantrine (Compound)
Anagrelide (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Halofantrine (Compound)
Anagrelide may cause a moderate interaction that could exacerbate di... |
DB00991 | DB01124 | 97 | 1,411 | [
"DDInter1358",
"DDInter1828"
] | Oxaprozin | Tolbutamide | Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Moderate | 1 | [
[
[
97,
24,
1411
]
],
[
[
97,
24,
959
],
[
959,
40,
1411
]
],
[
[
97,
63,
245
],
[
245,
40,
1411
]
],
[
[
97,
6,
6017
],
[
6017,
45,... | [
[
[
"Oxaprozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Oxaprozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide (Compound)
... |
DB00295 | DB00999 | 475 | 504 | [
"DDInter1244",
"DDInter883"
] | Morphine | Hydrochlorothiazide | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension.[A185138,L8447,L8450] Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and a... | Moderate | 1 | [
[
[
475,
24,
504
]
],
[
[
475,
24,
178
],
[
178,
1,
504
]
],
[
[
475,
24,
323
],
[
323,
40,
504
]
],
[
[
475,
21,
29561
],
[
29561,
... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrochlorothiazide"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polythiazide"
],
... | Morphine may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide and Polythiazide (Compound) resembles Hydrochlorothiazide (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Bendroflumethiazide and Bendroflumethiazide (Compound) resem... |
DB00581 | DB01118 | 355 | 33 | [
"DDInter1018",
"DDInter76"
] | Lactulose | Amiodarone | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its p... | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxic... | Moderate | 1 | [
[
[
355,
24,
33
]
],
[
[
355,
24,
540
],
[
540,
1,
33
]
],
[
[
355,
21,
28709
],
[
28709,
60,
33
]
],
[
[
355,
24,
688
],
[
688,
24,... | [
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
]
],
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
],
[
... | Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone and Dronedarone (Compound) resembles Amiodarone (Compound)
Lactulose (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Amiodarone (Compound)
Lactulose may cause a mode... |
DB01097 | DB11601 | 1,377 | 1,270 | [
"DDInter1033",
"DDInter1889"
] | Leflunomide | Tuberculin purified protein derivative | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Moderate | 1 | [
[
[
1377,
24,
1270
]
],
[
[
1377,
25,
350
],
[
350,
24,
1270
]
],
[
[
1377,
64,
550
],
[
550,
24,
1270
]
],
[
[
1377,
25,
119
],
[
119,
... | [
[
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carfilzomib"... | Leflunomide may lead to a major life threatening interaction when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Leflunomide may lead to a major life threatening interaction when taken with Trastuzumab and Tra... |
DB00860 | DB12332 | 891 | 1,619 | [
"DDInter1513",
"DDInter1626"
] | Prednisolone | Rucaparib | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
891,
24,
1619
]
],
[
[
891,
62,
307
],
[
307,
23,
1619
]
],
[
[
891,
24,
259
],
[
259,
24,
1619
]
],
[
[
891,
24,
151
],
[
151,
... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Prednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
... | Prednisolone may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacep... |
DB00773 | DB00900 | 896 | 45 | [
"DDInter702",
"DDInter544"
] | Etoposide | Didanosine | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-termi... | Moderate | 1 | [
[
[
896,
24,
45
]
],
[
[
896,
18,
7212
],
[
7212,
57,
45
]
],
[
[
896,
21,
28709
],
[
28709,
60,
45
]
],
[
[
896,
24,
36
],
[
36,
63... | [
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Didanosine"
]
],
[
[
"Etoposide",
"{u} (Compound) downregulates {v} (Gene)",
"HMG20B"
],
[
"HMG20B",
"{u} (Gene) is downregulated by {v... | Etoposide (Compound) downregulates HMG20B (Gene) and HMG20B (Gene) is downregulated by Didanosine (Compound)
Etoposide (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Didanosine (Compound)
Etoposide may cause a moderate interaction that could exacerbate diseases when... |
DB00990 | DB01041 | 1,547 | 770 | [
"DDInter705",
"DDInter1789"
] | Exemestane | Thalidomide | Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition. | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Major | 2 | [
[
[
1547,
25,
770
]
],
[
[
1547,
7,
7669
],
[
7669,
46,
770
]
],
[
[
1547,
21,
29425
],
[
29425,
60,
770
]
],
[
[
1547,
24,
4
],
[
4,
... | [
[
[
"Exemestane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
]
],
[
[
"Exemestane",
"{u} (Compound) upregulates {v} (Gene)",
"DDIT4"
],
[
"DDIT4",
"{u} (Gene) is upregulated by {v} (Compound)",
... | Exemestane (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Thalidomide (Compound)
Exemestane (Compound) causes Myocardial ischaemia (Side Effect) and Myocardial ischaemia (Side Effect) is caused by Thalidomide (Compound)
Exemestane may cause a moderate interaction that could exacerbate diseases w... |
DB00197 | DB01406 | 1,324 | 984 | [
"DDInter1881",
"DDInter472"
] | Troglitazone | Danazol | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders. | Moderate | 1 | [
[
[
1324,
24,
984
]
],
[
[
1324,
24,
989
],
[
989,
1,
984
]
],
[
[
1324,
24,
1561
],
[
1561,
40,
984
]
],
[
[
1324,
24,
222
],
[
222,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Danazol"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Progesterone"
],
[... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Progesterone and Progesterone (Compound) resembles Danazol (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Testosterone and Testosterone (Compound) resembles Danazol (Comp... |
DB00759 | DB09104 | 1,620 | 286 | [
"DDInter1783",
"DDInter1118"
] | Tetracycline | Magnesium hydroxide | Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some e... | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
1620,
24,
286
]
],
[
[
1620,
24,
1482
],
[
1482,
23,
286
]
],
[
[
1620,
63,
1252
],
[
1252,
23,
286
]
],
[
[
1620,
23,
1326
],
[
1326,... | [
[
[
"Tetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Tetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digitoxin"
... | Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and ... |
DB00804 | DB01019 | 1,507 | 427 | [
"DDInter543",
"DDInter199"
] | Dicyclomine | Bethanechol | Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.[A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may h... | Bethanechol is a synthetic ester that was initially synthesized in 1935.[A232905,L32539] As a cholinergic agent, bethanechol is similar in structure and pharmacological function to acetylcholine and is used in specific cases when stimulation of the parasympathetic nervous system is necessary.[A232905,L32539] For exampl... | Moderate | 1 | [
[
[
1507,
24,
427
]
],
[
[
1507,
6,
2720
],
[
2720,
45,
427
]
],
[
[
1507,
21,
28701
],
[
28701,
60,
427
]
],
[
[
1507,
63,
1442
],
[
1442... | [
[
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bethanechol"
]
],
[
[
"Dicyclomine",
"{u} (Compound) binds {v} (Gene)",
"CHRM3"
],
[
"CHRM3",
"{u} (Gene) is bound by {v} (Compound)"... | Dicyclomine (Compound) binds CHRM3 (Gene) and CHRM3 (Gene) is bound by Bethanechol (Compound)
Dicyclomine (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) is caused by Bethanechol (Compound)
Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Scopolamine an... |
DB08815 | DB13874 | 154 | 1,501 | [
"DDInter1104",
"DDInter639"
] | Lurasidone | Enasidenib | Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. | Enasidenib is an orally available treatment for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with specific mutations in the isocitrate dehydrogenase 2 (IDH2) gene, which is a recurrent mutation detected in 12-20% of adult patients with AML [A20344, A20345]. Patients eligible ... | Moderate | 1 | [
[
[
154,
24,
1501
]
],
[
[
154,
24,
1619
],
[
1619,
24,
1501
]
],
[
[
154,
64,
1419
],
[
1419,
24,
1501
]
],
[
[
154,
63,
1250
],
[
1250,
... | [
[
[
"Lurasidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enasidenib"
]
],
[
[
"Lurasidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
... | Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Enasidenib
Lurasidone may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a mode... |
DB00307 | DB09122 | 1,101 | 1,613 | [
"DDInter202",
"DDInter1409"
] | Bexarotene | Peginterferon beta-1a | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
1101,
24,
1613
]
],
[
[
1101,
24,
1627
],
[
1627,
24,
1613
]
],
[
[
1101,
23,
152
],
[
152,
24,
1613
]
],
[
[
1101,
24,
975
],
[
975,
... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
... | Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Bosentan a... |
DB00486 | DB00622 | 1,614 | 1,081 | [
"DDInter1253",
"DDInter1287"
] | Nabilone | Nicardipine | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [Pub... | Moderate | 1 | [
[
[
1614,
24,
1081
]
],
[
[
1614,
24,
409
],
[
409,
1,
1081
]
],
[
[
1614,
63,
1428
],
[
1428,
1,
1081
]
],
[
[
1614,
21,
28676
],
[
28676... | [
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nicardipine"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Felodipine"
],
[
... | Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Felodipine and Felodipine (Compound) resembles Nicardipine (Compound)
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Isradipine (Compound) resembles Nicardipine (Compound)
Na... |
DB00436 | DB01164 | 323 | 803 | [
"DDInter179",
"DDInter272"
] | Bendroflumethiazide | Calcium chloride | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810) | Calcium chloride is an ionic compound of calcium and chlorine. It is highly soluble in water and it is deliquescent. It is a salt that is solid at room temperature, and it behaves as a typical ionic halide. It has several common applications such as brine for refrigeration plants, ice and dust control on roads, and in ... | Moderate | 1 | [
[
[
323,
24,
803
]
],
[
[
323,
21,
28809
],
[
28809,
60,
803
]
],
[
[
323,
40,
504
],
[
504,
24,
803
]
],
[
[
323,
40,
178
],
[
178,
... | [
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium chloride"
]
],
[
[
"Bendroflumethiazide",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{... | Bendroflumethiazide (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Calcium chloride (Compound)
Bendroflumethiazide (Compound) resembles Hydrochlorothiazide (Compound) and Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Calcium chlor... |
DB00524 | DB11921 | 811 | 1,019 | [
"DDInter1199",
"DDInter492"
] | Metolazone | Deflazacort | A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Moderate | 1 | [
[
[
811,
24,
1019
]
],
[
[
811,
24,
959
],
[
959,
24,
1019
]
],
[
[
811,
1,
359
],
[
359,
24,
1019
]
],
[
[
811,
40,
1014
],
[
1014,
... | [
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Metolazone (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide may cause a moderate interaction tha... |
DB00211 | DB00852 | 1,290 | 1,445 | [
"DDInter1213",
"DDInter1545"
] | Midodrine | Pseudoephedrine | An ethanolamine derivative that is an adrenergic alpha agonist. It is used as a vasoconstrictor agent in the treatment of hypotension. | Pseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system.[A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889. The decongestant effect of pseud... | Moderate | 1 | [
[
[
1290,
24,
1445
]
],
[
[
1290,
63,
73
],
[
73,
24,
1445
]
],
[
[
1290,
24,
22
],
[
22,
40,
1445
]
],
[
[
1290,
6,
5214
],
[
5214,
... | [
[
[
"Midodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
]
],
[
[
"Midodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentermine"
],
... | Midodrine may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine
Midodrine may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ep... |
DB01100 | DB11110 | 1,568 | 603 | [
"DDInter1470",
"DDInter1115"
] | Pimozide | Magnesium citrate | A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug ... | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the ... | Moderate | 1 | [
[
[
1568,
24,
603
]
],
[
[
1568,
25,
57
],
[
57,
24,
603
]
],
[
[
1568,
64,
870
],
[
870,
24,
603
]
],
[
[
1568,
25,
484
],
[
484,
6... | [
[
[
"Pimozide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Pimozide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
"A... | Pimozide may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Pimozide may lead to a major life threatening interaction when taken with Fludrocortisone and Fludrocortisone ... |
DB00604 | DB01015 | 1,425 | 1,247 | [
"DDInter385",
"DDInter1724"
] | Cisapride | Sulfamethoxazole | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps i... | Minor | 0 | [
[
[
1425,
23,
1247
]
],
[
[
1425,
6,
3486
],
[
3486,
45,
1247
]
],
[
[
1425,
64,
11
],
[
11,
23,
1247
]
],
[
[
1425,
24,
688
],
[
688,
... | [
[
[
"Cisapride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
]
],
[
[
"Cisapride",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)... | Cisapride (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Sulfamethoxazole (Compound)
Cisapride may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Cisapride may cause a mod... |
DB00683 | DB11130 | 1,382 | 407 | [
"DDInter1212",
"DDInter1344"
] | Midazolam | Opium | Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazola... | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
1382,
24,
407
]
],
[
[
1382,
24,
662
],
[
662,
24,
407
]
],
[
[
1382,
63,
1233
],
[
1233,
24,
407
]
],
[
[
1382,
1,
481
],
[
481,
... | [
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
... | Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Triprolidine and Tripr... |
DB00013 | DB00159 | 1,255 | 940 | [
"DDInter1905",
"DDInter903"
] | Urokinase | Icosapent | Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978. | Important polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. A diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardiovascular disorders, prevents platelet aggregation, and inhibits arachidonic acid conve... | Moderate | 1 | [
[
[
1255,
24,
940
]
],
[
[
1255,
25,
500
],
[
500,
63,
940
]
],
[
[
1255,
24,
1347
],
[
1347,
63,
940
]
],
[
[
1255,
64,
942
],
[
942,
... | [
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Icosapent"
]
],
[
[
"Urokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxaparin"
],
[
"Enoxaparin",
... | Urokinase may lead to a major life threatening interaction when taken with Enoxaparin and Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Icosapent
Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may cause a... |
DB11767 | DB12674 | 1,583 | 975 | [
"DDInter1643",
"DDInter1105"
] | Sarilumab | Lurbinectedin | Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approve... | Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent fou... | Moderate | 1 | [
[
[
1583,
24,
975
]
],
[
[
1583,
63,
1613
],
[
1613,
24,
975
]
],
[
[
1583,
64,
1531
],
[
1531,
24,
975
]
],
[
[
1583,
24,
738
],
[
738,
... | [
[
[
"Sarilumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Sarilumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
... | Sarilumab may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Sarilumab may lead to a major life threatening interaction when taken with Canakinumab a... |
DB00694 | DB08895 | 51 | 976 | [
"DDInter485",
"DDInter1825"
] | Daunorubicin | Tofacitinib | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Major | 2 | [
[
[
51,
25,
976
]
],
[
[
51,
63,
1461
],
[
1461,
23,
976
]
],
[
[
51,
24,
214
],
[
214,
63,
976
]
],
[
[
51,
25,
982
],
[
982,
63,
... | [
[
[
"Daunorubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitami... | Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fos... |
DB00818 | DB01211 | 898 | 609 | [
"DDInter1538",
"DDInter393"
] | Propofol | Clarithromycin | Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associate... | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Moderate | 1 | [
[
[
898,
24,
609
]
],
[
[
898,
6,
10215
],
[
10215,
45,
609
]
],
[
[
898,
18,
7247
],
[
7247,
57,
609
]
],
[
[
898,
21,
28662
],
[
28662,
... | [
[
[
"Propofol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Propofol",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)... | Propofol (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Clarithromycin (Compound)
Propofol (Compound) downregulates NPDC1 (Gene) and NPDC1 (Gene) is downregulated by Clarithromycin (Compound)
Propofol (Compound) causes Tremor (Side Effect) and Tremor (Side Effect) is caused by Clarithromycin (Compound)
... |
DB00059 | DB08916 | 1,560 | 26 | [
"DDInter1404",
"DDInter32"
] | Pegaspargase | Afatinib | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal grow... | Moderate | 1 | [
[
[
1560,
24,
26
]
],
[
[
1560,
24,
883
],
[
883,
40,
26
]
],
[
[
1560,
24,
651
],
[
651,
24,
26
]
],
[
[
1560,
24,
1155
],
[
1155,
... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Afatinib"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Afatinib (Compound)
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin and Fosphenytoin may cause a moderate interaction that c... |
DB00261 | DB06081 | 702 | 1,046 | [
"DDInter93",
"DDInter286"
] | Anagrelide | Caplacizumab | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU i... | Major | 2 | [
[
[
702,
25,
1046
]
],
[
[
702,
23,
539
],
[
539,
62,
1046
]
],
[
[
702,
24,
1039
],
[
1039,
24,
1046
]
],
[
[
702,
24,
1427
],
[
1427,
... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Caplacizumab"
]
],
[
[
"Anagrelide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Capsicum",
... | Anagrelide may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Caplacizumab
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenf... |
DB00757 | DB08875 | 1,166 | 1,618 | [
"DDInter581",
"DDInter262"
] | Dolasetron | Cabozantinib | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
1166,
25,
1618
]
],
[
[
1166,
23,
112
],
[
112,
23,
1618
]
],
[
[
1166,
24,
1032
],
[
1032,
63,
1618
]
],
[
[
1166,
25,
1662
],
[
1662... | [
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Dolasetron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metroni... | Dolasetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol an... |
DB01611 | DB06699 | 1,487 | 774 | [
"DDInter893",
"DDInter493"
] | Hydroxychloroquine | Degarelix | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH... | Moderate | 1 | [
[
[
1487,
24,
774
]
],
[
[
1487,
63,
521
],
[
521,
1,
774
]
],
[
[
1487,
21,
29232
],
[
29232,
60,
774
]
],
[
[
1487,
63,
112
],
[
112,
... | [
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
... | Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin (Compound) resembles Degarelix (Compound)
Hydroxychloroquine (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Degarelix (Compound)
Hydroxychloroquine may cause a m... |
DB01149 | DB09082 | 851 | 659 | [
"DDInter1274",
"DDInter1934"
] | Nefazodone | Vilanterol | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
851,
24,
659
]
],
[
[
851,
24,
1220
],
[
1220,
23,
659
]
],
[
[
851,
63,
891
],
[
891,
23,
659
]
],
[
[
851,
64,
175
],
[
175,
2... | [
[
[
"Nefazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Nefazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[... | Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and ... |
DB09237 | DB11730 | 1,586 | 351 | [
"DDInter1045",
"DDInter1588"
] | Levamlodipine | Ribociclib | Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlod... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Moderate | 1 | [
[
[
1586,
24,
351
]
],
[
[
1586,
23,
466
],
[
466,
62,
351
]
],
[
[
1586,
24,
283
],
[
283,
62,
351
]
],
[
[
1586,
63,
597
],
[
597,
... | [
[
[
"Levamlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Levamlodipine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
... | Levamlodipine may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Levamlodipine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and ... |
DB00640 | DB01177 | 1,585 | 77 | [
"DDInter31",
"DDInter904"
] | Adenosine | Idarubicin | The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by [dipyridamole]... | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Moderate | 1 | [
[
[
1585,
24,
77
]
],
[
[
1585,
18,
10780
],
[
10780,
57,
77
]
],
[
[
1585,
21,
28890
],
[
28890,
60,
77
]
],
[
[
1585,
24,
823
],
[
823,
... | [
[
[
"Adenosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Adenosine",
"{u} (Compound) downregulates {v} (Gene)",
"CCNB2"
],
[
"CCNB2",
"{u} (Gene) is downregulated by {v} ... | Adenosine (Compound) downregulates CCNB2 (Gene) and CCNB2 (Gene) is downregulated by Idarubicin (Compound)
Adenosine (Compound) causes Myocardial infarction (Side Effect) and Myocardial infarction (Side Effect) is caused by Idarubicin (Compound)
Adenosine may cause a moderate interaction that could exacerbate diseases ... |
DB01037 | DB01168 | 1,161 | 1,053 | [
"DDInter1653",
"DDInter1526"
] | Selegiline | Procarbazine | A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual... | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Major | 2 | [
[
[
1161,
25,
1053
]
],
[
[
1161,
21,
28762
],
[
28762,
60,
1053
]
],
[
[
1161,
63,
480
],
[
480,
24,
1053
]
],
[
[
1161,
24,
1311
],
[
13... | [
[
[
"Selegiline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
]
],
[
[
"Selegiline",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Comp... | Selegiline (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Procarbazine (Compound)
Selegiline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Procarb... |
DB00860 | DB09065 | 891 | 760 | [
"DDInter1513",
"DDInter424"
] | Prednisolone | Cobicistat | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Moderate | 1 | [
[
[
891,
24,
760
]
],
[
[
891,
63,
1101
],
[
1101,
23,
760
]
],
[
[
891,
24,
555
],
[
555,
23,
760
]
],
[
[
891,
62,
523
],
[
523,
2... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
... | Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Netupitant and Netu... |
DB01050 | DB09054 | 848 | 384 | [
"DDInter900",
"DDInter905"
] | Ibuprofen | Idelalisib | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
848,
24,
384
]
],
[
[
848,
24,
222
],
[
222,
23,
384
]
],
[
[
848,
63,
1230
],
[
1230,
23,
384
]
],
[
[
848,
24,
1627
],
[
1627,
... | [
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopr... |
DB00427 | DB00434 | 1,233 | 13 | [
"DDInter1879",
"DDInter459"
] | Triprolidine | Cyproheptadine | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Moderate | 1 | [
[
[
1233,
24,
13
]
],
[
[
1233,
24,
104
],
[
104,
63,
13
]
],
[
[
1233,
63,
1302
],
[
1302,
24,
13
]
],
[
[
1233,
6,
10104
],
[
10104,
... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Protripty... |
DB00191 | DB00372 | 73 | 999 | [
"DDInter1447",
"DDInter1793"
] | Phentermine | Thiethylperazine | Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows thi... | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Moderate | 1 | [
[
[
73,
24,
999
]
],
[
[
73,
25,
318
],
[
318,
63,
999
]
],
[
[
73,
24,
1164
],
[
1164,
63,
999
]
],
[
[
73,
36,
1529
],
[
1529,
63,... | [
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
]
],
[
[
"Phentermine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Escitalopram"
],
[
"... | Phentermine may lead to a major life threatening interaction when taken with Escitalopram and Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine
Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipr... |
DB01115 | DB09340 | 336 | 1,013 | [
"DDInter1291",
"DDInter1895"
] | Nifedipine | Tyropanoic acid | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development,... | Tyropanoic acid is a radiocontrast agent used in cholecystography, the X-ray diagnosis of gallstones under the trade names include Bilopaque, Lumopaque, Tyropaque, and Bilopac. The molecule contains three heavy iodine atoms which obstruct X-rays in the same way as the calcium in bones, which results in a visible image ... | Moderate | 1 | [
[
[
336,
24,
1013
]
],
[
[
336,
1,
1081
],
[
1081,
24,
1013
]
],
[
[
336,
40,
409
],
[
409,
24,
1013
]
],
[
[
336,
63,
1431
],
[
1431,
... | [
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tyropanoic acid"
]
],
[
[
"Nifedipine",
"{u} (Compound) resembles {v} (Compound)",
"Nicardipine"
],
[
"Nicardipine",
"{u} may cause a ... | Nifedipine (Compound) resembles Nicardipine (Compound) and Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Tyropanoic acid
Nifedipine (Compound) resembles Felodipine (Compound) and Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Tyro... |
DB00314 | DB01129 | 894 | 379 | [
"DDInter288",
"DDInter1559"
] | Capreomycin | Rabeprazole | Cyclic peptide antibiotic similar to viomycin. It is produced by Streptomyces capreolus. | Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion. | Moderate | 1 | [
[
[
894,
24,
379
]
],
[
[
894,
24,
1215
],
[
1215,
40,
379
]
],
[
[
894,
24,
660
],
[
660,
1,
379
]
],
[
[
894,
63,
837
],
[
837,
1,... | [
[
[
"Capreomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rabeprazole"
]
],
[
[
"Capreomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lansoprazole"
],
... | Capreomycin may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and Lansoprazole (Compound) resembles Rabeprazole (Compound)
Capreomycin may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole (Compound) resembles Rabeprazole... |
DB00400 | DB11718 | 353 | 927 | [
"DDInter843",
"DDInter640"
] | Griseofulvin | Encorafenib | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
353,
24,
927
]
],
[
[
353,
24,
536
],
[
536,
24,
927
]
],
[
[
353,
63,
1010
],
[
1010,
24,
927
]
],
[
[
353,
24,
484
],
[
484,
6... | [
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secobarbital"
],
... | Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital and Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine a... |
DB00976 | DB06788 | 1,056 | 1,616 | [
"DDInter1758",
"DDInter864"
] | Telithromycin | Histrelin | Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with ... | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Moderate | 1 | [
[
[
1056,
24,
1616
]
],
[
[
1056,
62,
112
],
[
112,
23,
1616
]
],
[
[
1056,
24,
1342
],
[
1342,
24,
1616
]
],
[
[
1056,
24,
603
],
[
603,
... | [
[
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Telithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Telithromycin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Histrelin
Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin and... |
DB00277 | DB00635 | 1,031 | 1,573 | [
"DDInter1791",
"DDInter1515"
] | Theophylline | Prednisone | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Moderate | 1 | [
[
[
1031,
24,
1573
]
],
[
[
1031,
24,
175
],
[
175,
40,
1573
]
],
[
[
1031,
24,
251
],
[
251,
1,
1573
]
],
[
[
1031,
5,
11649
],
[
11649,
... | [
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
... | Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisone (Compound)
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Predni... |
DB00758 | DB01211 | 1,347 | 609 | [
"DDInter413",
"DDInter393"
] | Clopidogrel | Clarithromycin | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Moderate | 1 | [
[
[
1347,
24,
609
]
],
[
[
1347,
6,
4973
],
[
4973,
45,
609
]
],
[
[
1347,
7,
5409
],
[
5409,
46,
609
]
],
[
[
1347,
18,
8733
],
[
8733,
... | [
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Clopidogrel",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compoun... | Clopidogrel (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Clarithromycin (Compound)
Clopidogrel (Compound) upregulates SOCS2 (Gene) and SOCS2 (Gene) is upregulated by Clarithromycin (Compound)
Clopidogrel (Compound) downregulates PHGDH (Gene) and PHGDH (Gene) is downregulated by Clarithromycin (Compound)
C... |
DB04946 | DB06691 | 924 | 849 | [
"DDInter907",
"DDInter1155"
] | Iloperidone | Mepyramine | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
924,
24,
849
]
],
[
[
924,
63,
1594
],
[
1594,
24,
849
]
],
[
[
924,
6,
12523
],
[
12523,
45,
849
]
],
[
[
924,
24,
407
],
[
407,
... | [
[
[
"Iloperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Iloperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
... | Iloperidone may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Iloperidone (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Mepyramine (Compound)
Iloperidone may ... |
DB00712 | DB14115 | 1,274 | 1,312 | [
"DDInter763",
"DDInter868"
] | Flurbiprofen | Human botulinum neurotoxin A/B immune globulin | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Infant botulism is a rare infectious disease occurring in infants in which _Clostridium botulinum_ colonize the large intestine and being to produce botulinum neurotoxin directly in the gut. As these neurotoxins interfere with cholinergic nervous transmission, patients initially present with evident of loss of muscle t... | Major | 2 | [
[
[
1274,
25,
1312
]
],
[
[
1274,
24,
123
],
[
123,
24,
1312
]
],
[
[
1274,
24,
1132
],
[
1132,
25,
1312
]
],
[
[
1274,
64,
663
],
[
663,
... | [
[
[
"Flurbiprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Human botulinum neurotoxin A/B immune globulin"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ex... | Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Human botulinum neurotoxin A/B immune globulin
Flurbiprofen may cause a moderate interaction that could exacerbate diseases... |
DB01612 | DB08815 | 1,637 | 154 | [
"DDInter92",
"DDInter1104"
] | Amyl Nitrite | Lurasidone | Amyl Nitrite is an antihypertensive medicine. Amyl nitrite is employed medically to treat heart diseases such as angina and to treat cyanide poisoning. Its use as a prescription medicine comes from its ability to lower blood pressure. As an inhalant, it also has psychoactive effect which has led to illegal drug use. | Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. | Moderate | 1 | [
[
[
1637,
24,
154
]
],
[
[
1637,
63,
401
],
[
401,
24,
154
]
],
[
[
1637,
24,
849
],
[
849,
24,
154
]
],
[
[
1637,
24,
1450
],
[
1450,
... | [
[
[
"Amyl Nitrite",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
]
],
[
[
"Amyl Nitrite",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
... | Amyl Nitrite may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone
Amyl Nitrite may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine an... |
DB00295 | DB00679 | 475 | 684 | [
"DDInter1244",
"DDInter1796"
] | Morphine | Thioridazine | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Major | 2 | [
[
[
475,
25,
684
]
],
[
[
475,
24,
1237
],
[
1237,
40,
684
]
],
[
[
475,
25,
146
],
[
146,
40,
684
]
],
[
[
475,
25,
216
],
[
216,
1... | [
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thioridazine"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
],
[
"Clomiprami... | Morphine may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine (Compound) resembles Thioridazine (Compound)
Morphine may lead to a major life threatening interaction when taken with Propiomazine and Propiomazine (Compound) resembles Thioridazine (Compound)
Morphin... |
DB06824 | DB11348 | 29 | 1,065 | [
"DDInter1864",
"DDInter279"
] | Triethylenetetramine | Calcium Phosphate | Triethylenetatramine (TETA), also known as trientine, is a potent and selective copper (II)-selective chelator. It is a structural analog of linear polyamine compounds, [spermidine] and [spermine]. TETA was first developed in Germany in 1861 and its chelating properties were first recognized in 1925. Initially approved... | Calcium phosphate is typically available as an over the counter supplement, antacid, or as an added ingredient in some toothpastes [FDA Label] . | Moderate | 1 | [
[
[
29,
24,
1065
]
],
[
[
29,
23,
1193
],
[
1193,
63,
246
],
[
246,
24,
1065
]
],
[
[
29,
23,
1193
],
[
1193,
24,
943
],
[
943,
63,
... | [
[
[
"Triethylenetetramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Triethylenetetramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zi... | Triethylenetetramine may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a moderate interaction that could exacerbate diseases when taken with Gatifloxacin and Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB00581 | DB05316 | 355 | 749 | [
"DDInter1018",
"DDInter1467"
] | Lactulose | Pimavanserin | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its p... | Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors. Unlike other atypical antipsychotic... | Moderate | 1 | [
[
[
355,
24,
749
]
],
[
[
355,
24,
392
],
[
392,
24,
749
]
],
[
[
355,
63,
521
],
[
521,
24,
749
]
],
[
[
355,
24,
594
],
[
594,
63,... | [
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pimavanserin"
]
],
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
... | Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Pimavanserin
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin... |
DB08820 | DB12301 | 1,478 | 907 | [
"DDInter997",
"DDInter585"
] | Ivacaftor | Doravirine | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Doravirine is an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) intended to be administered in combination with other antiretroviral medicines.[L12729,L4562] Doravirine is available by itself or as a combination product of doravirine (100 mg), lamivudine (300 mg), and tenofovir disoproxil fumarate (300 mg... | Minor | 0 | [
[
[
1478,
23,
907
]
],
[
[
1478,
24,
159
],
[
159,
62,
907
]
],
[
[
1478,
63,
1213
],
[
1213,
23,
907
]
],
[
[
1478,
24,
951
],
[
951,
... | [
[
[
"Ivacaftor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doravirine"
]
],
[
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
... | Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a minor interaction that can limit clinical effects when taken with Doravirine
Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasat... |
DB00008 | DB01265 | 491 | 1,477 | [
"DDInter1407",
"DDInter1757"
] | Peginterferon alfa-2a | Telbivudine | Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Telbivudine is a synthetic thymidine nucleoside analog with specific activity against the hepatitis B virus. Telbivudine is orally administered, with good tolerance, lack of toxicity and no dose-limiting side effects. | Major | 2 | [
[
[
491,
25,
1477
]
],
[
[
491,
24,
139
],
[
139,
1,
1477
]
],
[
[
491,
24,
112
],
[
112,
24,
1477
]
],
[
[
491,
24,
850
],
[
850,
6... | [
[
[
"Peginterferon alfa-2a",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Telbivudine"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
],
... | Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine (Compound) resembles Telbivudine (Compound)
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a mo... |
DB00319 | DB00563 | 790 | 663 | [
"DDInter1474",
"DDInter1174"
] | Piperacillin | Methotrexate | Semisynthetic, broad-spectrum, ampicillin derived ureidopenicillin antibiotic proposed for pseudomonas infections. It is also used in combination with other antibiotics. | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Major | 2 | [
[
[
790,
25,
663
]
],
[
[
790,
6,
10612
],
[
10612,
45,
663
]
],
[
[
790,
18,
10103
],
[
10103,
45,
663
]
],
[
[
790,
7,
15917
],
[
15917,... | [
[
[
"Piperacillin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methotrexate"
]
],
[
[
"Piperacillin",
"{u} (Compound) binds {v} (Gene)",
"SLC22A6"
],
[
"SLC22A6",
"{u} (Gene) is bound by {v} (Compound)",
... | Piperacillin (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Methotrexate (Compound)
Piperacillin (Compound) downregulates FPGS (Gene) and FPGS (Gene) is bound by Methotrexate (Compound)
Piperacillin (Compound) upregulates ANKRD10 (Gene) and ANKRD10 (Gene) is downregulated by Methotrexate (Compound)
Pipe... |
DB00928 | DB08895 | 1,426 | 976 | [
"DDInter148",
"DDInter1825"
] | Azacitidine | Tofacitinib | Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity.[A1406,A1413,A1415] Two main mechanisms of action have been proposed for azacitidine. One of them is the induction of cytotoxicity. ... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Major | 2 | [
[
[
1426,
25,
976
]
],
[
[
1426,
63,
1461
],
[
1461,
23,
976
]
],
[
[
1426,
24,
200
],
[
200,
63,
976
]
],
[
[
1426,
24,
1430
],
[
1430,
... | [
[
[
"Azacitidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Azacitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin ... | Azacitidine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Azacitidine may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and C... |
DB00099 | DB00762 | 440 | 613 | [
"DDInter735",
"DDInter973"
] | Filgrastim | Irinotecan | Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the seq... | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Moderate | 1 | [
[
[
440,
24,
613
]
],
[
[
440,
24,
869
],
[
869,
63,
613
]
],
[
[
440,
63,
599
],
[
599,
24,
613
]
],
[
[
440,
24,
1555
],
[
1555,
2... | [
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Irinotecan"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
... | Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuz... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.